ReviewWorld journal of gastrointestinal pathophysiology2014
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?
Review in World journal of gastrointestinal pathophysiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?Redox biology · 2015Pooled it
- Recurrent Ulceration and Disease at the Ileocolonic Anastomosis in Crohn's Disease: Etiology, Prevention, and Management, a Review Article.Journal of clinical medicine · 2025Review
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.Intestinal research · 2024Review
- Bariatric Surgery and Inflammatory Bowel Disease: National Trends and Outcomes Associated with Procedural Sleeve Gastrectomy vs Historical Bariatric Surgery Among US Hospitalized Patients 2009-2020.Obesity surgery · 2023Article
- Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases.International journal of molecular sciences · 2021Review
- The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease.Nutrients · 2021Review
- Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice.Scientific reports · 2021Article
- Impact of 6-Month Exposure to Aerosols From Potential Modified Risk Tobacco Products Relative to Cigarette Smoke on the Rodent Gastrointestinal Tract.Frontiers in microbiology · 2021Article
- Coptidis Rhizoma-Contained Traditional Formulae for Insomnia: A Potential to Prevent Diabetes?Chinese journal of integrative medicine · 2018Article
- Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease.Cell death & disease · 2018Article
- Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages.Frontiers in immunology · 2018Review
- A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information.Gastroenterology and hepatology from bed to bench · 2017Article
- The dual role of Escherichia coli in the course of ulcerative colitis.BMC gastroenterology · 2016Article
- May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis?World journal of gastroenterology · 2016Article
- Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.World journal of gastroenterology · 2016Review
- Simultaneous purification of DNA and RNA from microbiota in a single colonic mucosal biopsy.BMC research notes · 2016Article
- Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association.World journal of gastroenterology · 2016Review
- Current Understanding of Dysbiosis in Disease in Human and Animal Models.Inflammatory bowel diseases · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), namely Crohn's disease and ulcerative colitis, are lifelong chronic disorders arising from interactions among genetic, immunological and environmental factors. Although the origin of IBDs is closely linked to immune response alterations, which governs most medical decision-making, recent findings suggest that gut microbiota may be involved in IBD pathogenesis. Epidemiologic evidence and several studies have shown that a dysregulation of gut microbiota (i.e., dysbiosis) may trigger the onset of intestinal disorders such as IBDs. Animal and human investigations focusing on the microbiota-IBD relationship have suggested an altered balance of the intestinal microbial population in the active phase of IBD. Rigorous microbiota typing could, therefore, soon become part of a complete phenotypic analysis of IBD patients. Moreover, individual susceptibility and environmental triggers such as nutrition, medications, age or smoking could modify bacterial strains in the bowel habitat. Pharmacological manipulation of bowel microbiota is somewhat controversial. The employment of antibiotics, probiotics, prebiotics and synbiotics has been widely addressed in the literature worldwide, with the aim of obtaining positive results in a number of IBD patient settings, and determining the appropriate timing and modality of this intervention. Recently, novel treatments for IBDs, such as fecal microbiota transplantation, when accepted by patients, have shown promising results. Controlled studies are being designed. In the near future, new therapeutic strategies can be expected, with non-pathogenic or modified food organisms that can be genetically modified to exert anti-inflammatory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.